AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 91 min read$PCVX

Wassil Jim sold $164K of PCVX

Wassil Jim (EVP, Chief Scientific Ofc, COO) sold 2,715 shares of Vaxcyte, Inc. (PCVX) at an average of $60.35 ($59.52–$61.16, $0.16M total) across 2 trades over 2026-09-04 to 2026-09-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wassil Jim
Published Sep 9, 2026, 9:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 9:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PCVX
Neutral
high confidence
Mentioned
$PCVX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PCVXNeutralLow
01

Why it matters

The disclosed sale is modest and part of a pre‑arranged 10b5‑1 plan, suggesting no immediate market impact.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming clinical trial results not disclosed.

Relevance 3/10Novelty 3/10Timing: filed Sep 9 2026 (post‑market)

Background

Form 4 filings provide the first public record of insider transactions.

Company-level read

Ticker impact

$PCVXNeutralHigh confidence
Context

SEC Form 4 disclosed insider Wassil Jim sold 2,715 shares for $163,862, a routine insider sale.

Expected impact

No material impact expected.

Evidence & confidence

Sale size is small relative to holdings and market cap; typical 10b5‑1 plan.

Market effects

Sector

None; biotech sector unchanged.

Regional

None; US market unaffected.

Global

None

Counterpoint

What could challenge this read

Even small insider sales can signal upcoming negative news.

Key entities

  • Company
    Vaxcyte, Inc.

    Biotech firm developing mRNA vaccines (NASDAQ: PCVX).

  • Insider
    Wassil Jim

    Executive Vice President, Chief Scientific Officer, COO.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PCVX insider trading history →

Related articles

SEP 6
$PCVXMed

The Next Year Will Define Vaxcyte’s (PCVX) Vaccine Gamble

Vaxcyte (PCVX) reported a near-doubled net loss of $284.3M in Q2, with key Phase 3 trial results for its pneumococcal vaccine candidate VAX-31 expected by late 2026. The company has $2.5B in cash and added vaccine industry veterans to its board. Success hinges on upcoming clinical data.

yahoo.com3 min
AUG 5
$PCVXMed

Vaxcyte, Inc. (PCVX): Results of Operations and Financial Condition

Vaxcyte, Inc. (PCVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half

SEC EDGAR 8-K6 min